Page 42 - Recursion Pharmaceuticals News Today

Tech giants will be pushed into the spotlight with Apple (NASDAQ:AAPL), Amazon, Microsoft (MSFT), Alphabet (GOOG), Meta Platforms (META), and Intel (NASDAQ:INTC) all on the earnings stage.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) is one of 254 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare Recursion Pharmaceuticals to related businesses based on the strength of its dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Insider & Institutional Ownership […]

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) is one of 254 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Recursion Pharmaceuticals to related companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings. Valuation and Earnings This […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) CEO Christopher Gibson sold 35,836 shares of the business’s stock in a transaction dated Monday, April 18th. The shares were sold at an average price of $6.84, for a total value of $245,118.24. Following the sale, the chief executive officer now owns 394,791 shares in the company, valued […]

In this piece, we will take a look at the nine healthcare stocks to invest in today according to Stanley Druckenmiller.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) is one of 254 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Recursion Pharmaceuticals to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings. Valuation and […]

In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) is one of 254 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Recursion Pharmaceuticals to similar companies based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, profitability and earnings. Valuation & Earnings This […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) CEO Christopher Gibson sold 36,718 shares of the firm’s stock in a transaction dated Thursday, April 7th. The stock was sold at an average price of $6.54, for a total value of $240,135.72. Following the completion of the transaction, the chief executive officer now owns 314,534 shares of […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating)’s stock price fell 10.3% during mid-day trading on Wednesday . The stock traded as low as $6.36 and last traded at $6.39. 22,116 shares traded hands during trading, a decline of 98% from the average session volume of 1,356,780 shares. The stock had previously closed at $7.12. RXRX […]